Rat model market seen reaching $2.8 billion by 2030

The rat model market is projected to grow from $1.75 billion in 2025 to $2.8 billion by 2030, driven by drug development, biomedical research and growing use of gene-editing and humanized rat platforms. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Rat models are a core tool in biomedical research and drug discovery because they help simulate human disease, test drug efficacy and evaluate compounds in preclinical settings. - The market’s projected rise signals continued demand for cost-effective animal models as pharmaceutical and academic research expands.

What happened: - The rat model market is projected to grow from $1.75 billion in 2025 to $1.92 billion in 2026. - The Business Research Company forecast the market will reach $2.8 billion by 2030. - The report estimates a 9.4% CAGR from 2025 to 2026 and a 9.9% CAGR through 2030. - The report was published Aug. 26, 2026, as The Business Research Company’s Rat Model Global Market Report 2026. - A free sample of the report is available. - The full rat model market report is also available.

The details: - Rising biomedical research activity, broader use of animal models in drug development, growth in academic research institutions, availability of inbred and outbred rat strains and higher demand for toxicology testing supported earlier market growth. - Future growth is expected to come from investment in precision medicine, demand for predictive disease models, expanded gene-editing applications, pressure to lower clinical trial failure rates and wider adoption of humanized rat platforms. - Key trends include rising use of CRISPR-based rat models, demand for immunodeficient and humanized rats, stronger preclinical disease modeling, advances in genetic editing and a push for better translational research accuracy. - Rat models use rat genes, cells, tissues and organs to replicate healthy and disease conditions of the human immune system. - Humanized rats are used in preclinical research to model human disease and study the impact of compounds on human proteins. - The report says the need for new and effective medicines is a primary demand driver. - Rats are favored in research because they are smaller and easier to maintain than more complex mammals such as primates, which makes them a lower-cost option. - In July 2024, the National Center for Biotechnology Information reported U.S. medicine spending rose 13.6% in 2023 to $722.5 billion.

Between the lines: - The forecast points to a broader shift toward more predictive preclinical tools as drugmakers try to improve translational accuracy before human trials. - The emphasis on CRISPR, humanized rats and immunodeficient rats suggests research demand is moving toward more specialized models rather than general-purpose animal testing. - North America held the largest market share in 2025, reflecting its research infrastructure and pharmaceutical base. - Asia-Pacific is expected to be the fastest-growing region during the forecast period as biomedical research and investment expand. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - Market growth is expected to continue through 2030 as precision medicine, gene editing and preclinical model development gain traction. - Expanded adoption of humanized rat platforms and CRISPR-based models is likely to shape the next phase of product and research demand. - The Business Research Company says its 2026 market reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - The company also provided contact details and social media links for follow-up, including LinkedIn, Facebook and X/Twitter.